Rhenman & Partners Asset Management Ab Syndax Pharmaceuticals Inc Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 259,500 shares of SNDX stock, worth $4.14 Million. This represents 0.42% of its overall portfolio holdings.
Number of Shares
259,500
Previous 228,500
13.57%
Holding current value
$4.14 Million
Previous $4.69 Million
6.48%
% of portfolio
0.42%
Previous 0.46%
Shares
3 transactions
Others Institutions Holding SNDX
# of Institutions
227Shares Held
88.3MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$126 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$93.2 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$79.5 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$77.9 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$65.5 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $902M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...